Skip to main content
Premium Trial:

Request an Annual Quote

OncoVista Sells AdnaGen for up to $83M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OncoVista Innovative Therapies announced that it has sold its majority stake in tumor diagnostics subsidiary AdnaGen to an entity called Alere Holdings Bermuda Limited Canon's Court.

Under the terms of the deal, OncoVista, based in San Antonio, Texas, will receive an upfront payment of $10 million, milestone payments of up to $10 million related to certain financial goals being met within 24 months, and milestone payments of up to $63 million related to clinical, regulatory, and sales goals being met within 36 months.

OncoVista is receiving up to $65 million in cash as part of the deal, and said in a statement that it is entitled to receive its pro rata portion of about 78 percent of the entire $83 million offer.

OncoVista acquired AdnaGen in 2006, and owned about 78 percent of the Langenhagen, Germany-based firm.

AdnaGen is developing molecular diagnostic tests for breast, prostate, and colorectal cancers.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.